Identification of Tipifarnib Sensitivity Biomarkers in T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoma

Overview

Journal Sci Rep

Specialty Science

Date 2020 Apr 23

PMID 32317694

Citations 6

Authors

Ruth Alonso-Alonso

Rufino Mondejar

Nerea Martinez

Nuria Garcia-Diaz

Cristina Perez

David Merino

Marta Rodriguez

Anna Esteve-Codina

Berta Fuste

Marta Gut

Francis Burrows

Catherine Scholz

Jose Pedro Vaque

Antonio Gualberto

Miguel Angel Piris

Affiliations

Soon will be listed here.

Abstract

Patients diagnosed with T-cell leukemias and T-cell lymphomas (TCLs) still have a poor prognosis and an inadequate response to current therapies, highlighting the need for targeted treatments. We have analyzed the potential therapeutic value of the farnesyltransferase inhibitor, tipifarnib, in 25 TCL cell lines through the identification of genomic and/or immunohistochemical markers of tipifarnib sensitivity. More than half of the cell lines (60%) were considered to be sensitive. Tipifarnib reduced cell viability in these T-cell leukemia and TCL cell lines, induced apoptosis and modified the cell cycle. A mutational study showed TP53, NOTCH1 and DNMT3 to be mutated in 84.6%, 69.2% and 30.0% of sensitive cell lines, and in 62.5%, 0% and 0% of resistant cell lines, respectively. An immunohistochemistry study showed that p-ERK and RelB were associated as potential biomarkers of tipifarnib sensitivity and resistance, respectively. Data from RNA-seq show that tipifarnib at IC after 72 h downregulated a great variety of pathways, including those controlling cell cycle, metabolism, and ribosomal and mitochondrial activity. This study establishes tipifarnib as a potential therapeutic option in T-cell leukemia and TCL. The mutational state of NOTCH1, p-ERK and RelB could serve as potential biomarkers of tipifarnib sensitivity and resistance.

Citing Articles

The mitochondria as an emerging target of self-renewal in T-cell acute lymphoblastic leukemia.

Al-Hamaly M, Winter E, Blackburn J Cancer Biol Ther. 2025; 26(1):2460252.

PMID: 39905687 PMC: 11801350. DOI: 10.1080/15384047.2025.2460252.

Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma.

Witzig T, Sokol L, Kim W, de la Cruz Vicente F, Garcia-Sancho A, Advani R Blood Adv. 2024; 8(17):4581-4592.

PMID: 38991123 PMC: 11401221. DOI: 10.1182/bloodadvances.2024012806.

Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure.

Mallaredy V, Roy R, Cheng Z, Thej C, Benedict C, Truongcao M Circ Res. 2024; 135(2):280-297.

PMID: 38847080 PMC: 11223950. DOI: 10.1161/CIRCRESAHA.123.324110.

Sphingolipids and Lymphomas: A Double-Edged Sword.

Pherez-Farah A, Lopez-Sanchez R, Villela-Martinez L, Ortiz-Lopez R, Beltran B, Hernandez-Hernandez J Cancers (Basel). 2022; 14(9).

PMID: 35565181 PMC: 9104519. DOI: 10.3390/cancers14092051.

Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation.

Greenberg J, Kim H, Ahn M, Moustafa A, Zhou H, Barata P Cancers (Basel). 2022; 14(4).

PMID: 35205655 PMC: 8870174. DOI: 10.3390/cancers14040903.

References

Coiffier B, Federico M, Caballero D, Dearden C, Morschhauser F, Jager U . Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treat Rev. 2014; 40(9):1080-8. DOI: 10.1016/j.ctrv.2014.08.001. View

Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho A, Metzner B . Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010; 116(18):3418-25. DOI: 10.1182/blood-2010-02-270785. View

Patrick K, Wade R, Goulden N, Mitchell C, Moorman A, Rowntree C . Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014; 166(3):421-4. DOI: 10.1111/bjh.12882. View

DAmore F, Gaulard P, Trumper L, Corradini P, Kim W, Specht L . Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v108-15. DOI: 10.1093/annonc/mdv201. View

Mondejar R, Perez C, Onaindia A, Martinez N, Gonzalez-Rincon J, Pisonero H . Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines. PLoS One. 2017; 12(5):e0177524. PMC: 5432176. DOI: 10.1371/journal.pone.0177524. View

Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J . Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015; 47(11):1304-15. DOI: 10.1038/ng.3415. View

Kiel M, Sahasrabuddhe A, Rolland D, Velusamy T, Chung F, Schaller M . Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome. Nat Commun. 2015; 6:8470. PMC: 4598843. DOI: 10.1038/ncomms9470. View

Manso R, Rodriguez-Pinilla S, Gonzalez-Rincon J, Gomez S, Monsalvo S, Llamas P . Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas. Haematologica. 2014; 100(1):e25-7. PMC: 4281331. DOI: 10.3324/haematol.2014.113696. View

Perez C, Gonzalez-Rincon J, Onaindia A, Almaraz C, Garcia-Diaz N, Pisonero H . Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. Haematologica. 2015; 100(11):e450-3. PMC: 4825308. DOI: 10.3324/haematol.2015.132837. View

10.

Vaque J, Gomez-Lopez G, Monsalvez V, Varela I, Martinez N, Perez C . PLCG1 mutations in cutaneous T-cell lymphomas. Blood. 2014; 123(13):2034-43. DOI: 10.1182/blood-2013-05-504308. View

11.

Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson M . The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017; 49(8):1211-1218. PMC: 5535770. DOI: 10.1038/ng.3909. View

12.

Zhang J, Ding L, Holmfeldt L, Wu G, Heatley S, Payne-Turner D . The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481(7380):157-63. PMC: 3267575. DOI: 10.1038/nature10725. View

13.

Palomero T, Ferrando A . Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S205-10. PMC: 2814179. DOI: 10.3816/CLM.2009.s.013. View

14.

Sulong S, Moorman A, Irving J, Strefford J, Konn Z, Case M . A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood. 2008; 113(1):100-7. DOI: 10.1182/blood-2008-07-166801. View

15.

Degryse S, de Bock C, Cox L, Demeyer S, Gielen O, Mentens N . JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014; 124(20):3092-100. DOI: 10.1182/blood-2014-04-566687. View

16.

Zenatti P, Ribeiro D, Li W, Zuurbier L, Silva M, Paganin M . Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011; 43(10):932-9. PMC: 7424552. DOI: 10.1038/ng.924. View

17.

Goemans B, Zwaan C, Harlow A, Loonen A, Gibson B, Hahlen K . In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood. 2005; 106(10):3532-7. DOI: 10.1182/blood-2005-04-1640. View

18.

Karp J, Lancet J, Kaufmann S, End D, Wright J, Bol K . Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001; 97(11):3361-9. DOI: 10.1182/blood.v97.11.3361. View

19.

ORegan R, Khuri F . Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?. Endocr Relat Cancer. 2004; 11(2):191-205. DOI: 10.1677/erc.0.0110191. View

20.

End D, Smets G, Todd A, Applegate T, Fuery C, Angibaud P . Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001; 61(1):131-7. View